



ASX Announcement | 18 September 2020
Noxopharm Limited (ASX:NOX)

Noxopharm Appoints US Corporate Advisory and Consulting Firm

Sydney, 18 September 2020: Australian clinical-stage drug development company **Noxopharm Limited (ASX:NOX)** is pleased to announce that it has appointed US corporate advisory and consulting firm, Destum Partners, to advise on its immuno-oncology drug business.

Destum in the first instance will advise specifically on the Company's DARRT program and the opportunity it offers as a treatment for end-stage prostate cancer, leading onto transaction advice on strategic partnerships, licensing and merger and acquisition deals.

Immuno-oncology (I-O) therapy is the emerging force in oncology, offering the opportunity for dramatic anti-cancer responses. However, current I-O therapies including CAR-T therapy and immune checkpoint inhibitors are expensive (with the average I-O cost in the U.S. estimated at 4 times the average U.S. household income¹) and their benefit is limited to a relatively small number of cancer types (eg. melanoma, lung cancer, bladder cancer²).

Noxopharm believes that its DARRT treatment regimen comprising a combination of Veyonda® and low-dose radiotherapy offers a considerably more cost-effective, more accessible and better tolerated I-O treatment across more cancer types.

Noxopharm CEO, Dr Graham Kelly, said: "The I-O therapy market currently generates sales of about US\$30 billion p.a., and that is regarded as just the tip of the iceberg given the current limited response rates. Every major pharma company is looking for a way to become involved in this rapidly expanding market. We believe that Veyonda® and the DARRT regimen have enormous potential value. The appointment of Destum is intended to help ensure that we maximise that value."

Destum Partners is a boutique advisory and consulting firm focused on creating value for biopharma companies through transformative deals, and empowering decision making through unparalleled insight. Its Advisory Practice has completed over US\$3 billion in deals, with a variety of deal structures, and across a range of therapeutic areas and geographies. Its consulting practice has completed over 200 successful engagements, including many specifically in oncology.

References.

1. Verma V et al (2018) A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. *J Immunother Cancer* 6:128 <https://doi.org/10.1186/s40425-018-0442-7>
2. Linda T, Theodorescu D (2020) *Determinants of resistance to checkpoint inhibitors*. *Int J Mol Sci* 21:1594

Graham Kelly, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

-ENDS-



About Noxopharm

Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and septic shock.

Veyonda® is the Company's first pipe-line drug candidate currently in Phase 2 clinical trialling. Veyonda® has two main drug actions – inhibition of sphingosine kinase and inhibition of STING signalling. Activity against the former target contributes to its dual-acting oncotoxic and immuno-oncology functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiotherapy and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, also contributing to an anti-cancer action, but also potentially blocking sepsis.

Noxopharm also is the major shareholder of US biotechnology company Nyrada Inc (ASX:NYR).

To learn more, please visit: noxopharm.com

Investor & Corporate enquiries:

Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

Company Secretary:

David Franks
T: +61 2 8072 1400
E: David.Franks@automicgroup.com.au

Media Enquiries

Julia Maguire
The Capital Network
E: julia@thecapitalnetwork.com.au
T: + 61 2 8999 3699

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.